This company invites all interested, both current investors and potential investors to participate in this event, ask questions directly on this page before the event starts and upvote those questions you would like addressed.
The company will address as many questions as possible, and focus on those questions most wanted by investors.
You have not put any numbers on the revenue growth the coming years in regards to the rights issue. Do you have any estimates or when can we expect to get a guidance for 2024 for example?
With the high amount of studies done around SuPAR what is the reason for suPAR not yet being used at a high extense in clinical use?
In 2023 you have seen a growth in the US of over 70%, if I calculate correctly. What has been the main driver of this growth and what have you done in this market to secure this growth compared to europe? Do you expect this trend to continue in 2024?
What do you expect the volume or sales should be to reach breakeven and for you to fund the ongoing growth with your own cash flow?
Do you have any customers where your products has been to begin with in the research department and from there spread out to clinical use based on that research or are those two things usually not connected?
Previously I have heard that in the US private hospitals and care facilities can be more open to solutions like Virogates as they are a for-profit business looking to increase their profits while providing better care for each patient, is that true? And if it is how will you make sure to benefit from this in the future and can you take the same approach in Europe for private hospitals?